Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -21.63
- Piotroski Score 5.00
- Grade Buy
- Symbol (CANF)
- Company Can-Fite BioPharma Ltd.
- Price $2.00
- Changes Percentage (1.54%)
- Change $0.03
- Day Low $1.94
- Day High $2.04
- Year High $4.69
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/28/2024
- Fiscal Year End N/A
- Average Stock Price Target $10.00
- High Stock Price Target $10.00
- Low Stock Price Target $10.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.00
- Trailing P/E Ratio -0.82
- Forward P/E Ratio -0.82
- P/E Growth -0.82
- Net Income $-7,634,000
Income Statement
Quarterly
Annual
Latest News of CANF
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Is Can-Fite BioPharma Ltd. (CANF) The Best Rated Penny Stock To Buy According to Analysts?
An article lists the top 10 penny stocks, focusing on Can-Fite BioPharma Ltd. Analysts predict a 317% upside potential for CANF due to its innovative treatments in the biopharmaceutical sector....
By Yahoo! Finance | 1 month ago -
Insider Sale: EVP & CFO Stuart Canfield Sells 3,000 Shares of Electronic Arts Inc (EA)
Stuart Canfield, CFO of Electronic Arts Inc, sold 3,000 shares at $145 per share. He now owns 7,553 shares. EA is a leading digital entertainment company. Canfield has sold 9,259 shares in the past ye...
By Yahoo! Finance | 2 months ago -
Insider Sale: EVP & CFO Stuart Canfield Sells 1,500 Shares of Electronic Arts Inc (EA)
On June 25, 2024, Stuart Canfield, CFO of Electronic Arts Inc (NASDAQ:EA), sold 1,500 shares at $141.01 per share. Canfield now owns 10,553 shares. EA is a leading global digital entertainment company...
By Yahoo! Finance | 3 months ago
